Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Insulin,Glucagon
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Helmsley Charitable Trust
Deal Size : Undisclosed
Deal Type : Financing
Abvance Gets $3.9M Investment from Helmsley Trust For Insulin-Glucagon Drug
Details : The funding will support the pre-clinical development of ABV100, the Company’s initial proprietary insulin-glucagon combination candidate developing to treat diabetes.
Brand Name : ABV100
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : Insulin,Glucagon
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Helmsley Charitable Trust
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?